STOK Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
9.3M
+49.7%
6.2M
+344.3%
1.4M
-86.8%
10.6M
-23.1%
13.8M
Cost of Revenue
0
0
0
0
0
Gross Profit
9.3M
+49.7%
6.2M
+344.3%
1.4M
-86.8%
10.6M
-23.1%
13.8M
Operating Expenses
74.8M
+25.3%
59.6M
-5.1%
62.8M
+17.0%
53.7M
+30.7%
41.1M
R&D
49.5M
+24.8%
39.7M
-4.8%
41.7M
+10.6%
37.7M
+45.8%
25.9M
SG&A
25.3M
+26.4%
20.0M
-5.5%
21.1M
+31.9%
16.0M
+5.0%
15.3M
Operating Income
-65429000
-22.5%
-53418000
+13.1%
-61439000
-42.6%
-43091000
-57.8%
-27300000
EBITDA
-65429000
-23.5%
-52979000
+13.2%
-61034000
-43.1%
-42649000
-56.2%
-27300000
Net Income
-61618000
-23.2%
-50003000
+13.7%
-57934000
-51.1%
-38347000
-63.3%
-23483000
EPS (Basic)
$-0.93
-17.7%
$-0.79
+15.1%
$-0.93
-43.1%
$-0.65
-62.5%
$-0.40
EPS (Diluted)
$-0.93
-17.7%
$-0.79
+17.7%
$-0.96
-47.7%
$-0.65
-62.5%
$-0.40
Shares (Diluted)
66.0M
+4.7%
63.1M
+4.2%
60.5M
+3.2%
58.6M
+0.4%
58.4M
Stoke Therapeutics (STOK) โ€” Financials